LeMaitre Vascular (NASDAQ:LMAT) Upgraded by BidaskClub to Sell

BidaskClub upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a strong sell rating to a sell rating in a research note issued to investors on Tuesday, January 16th.

A number of other equities research analysts have also issued reports on the company. Zacks Investment Research lowered LeMaitre Vascular from a buy rating to a hold rating in a research note on Thursday, September 28th. Canaccord Genuity lowered their price objective on LeMaitre Vascular from $30.00 to $29.00 and set a hold rating for the company in a research note on Friday, October 27th. First Analysis lowered LeMaitre Vascular from an overweight rating to an equal weight rating and set a $34.00 price objective for the company. in a research note on Friday, October 27th. Benchmark lowered LeMaitre Vascular from a buy rating to a hold rating in a research report on Friday, October 27th. Finally, Stifel Nicolaus reiterated a buy rating on shares of LeMaitre Vascular in a research report on Sunday, October 29th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $32.20.

LeMaitre Vascular (NASDAQ LMAT) opened at $34.13 on Tuesday. The company has a market capitalization of $657.51, a PE ratio of 44.32, a PEG ratio of 2.63 and a beta of 0.53. LeMaitre Vascular has a twelve month low of $19.82 and a twelve month high of $39.88.

Institutional investors have recently made changes to their positions in the business. 361 Capital LLC bought a new stake in LeMaitre Vascular during the 3rd quarter valued at $1,973,000. BNP Paribas Arbitrage SA raised its stake in LeMaitre Vascular by 97.6% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 7,405 shares of the medical instruments supplier’s stock valued at $277,000 after acquiring an additional 3,657 shares in the last quarter. Allianz Asset Management GmbH raised its stake in LeMaitre Vascular by 4.7% during the 3rd quarter. Allianz Asset Management GmbH now owns 321,820 shares of the medical instruments supplier’s stock valued at $12,042,000 after acquiring an additional 14,306 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in LeMaitre Vascular by 4.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 968,232 shares of the medical instruments supplier’s stock valued at $30,228,000 after acquiring an additional 40,767 shares in the last quarter. Finally, State Street Corp increased its position in shares of LeMaitre Vascular by 25.2% during the 2nd quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock valued at $11,951,000 after purchasing an additional 77,009 shares during the period. 71.64% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://stocknewstimes.com/2018/02/11/lemaitre-vascular-lmat-raised-to-sell-at-bidaskclub.html.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply